Disease progression model anchored around clinical diagnosis in longitudinal cohorts: example of Alzheimer’s disease and related dementia

• Published in: BMC medical research methodology 2023-09, Vol.23 (1), p.1-199, Article 199
• Main Authors: Lespinasse, Jérémie, Dufouil, Carole, Proust-Lima, Cécile
• Format: Article
• Language: English
• Subjects: Age; Alzheimer's disease; Amyloid beta-protein; Analysis; Atrophy; Biomarkers; Care and treatment; Cognitive ability; Dementia; Development and progression; Diagnosis; Disease progression model; Latent time; Life Sciences; Magnetic resonance imaging; Medical diagnosis; Medical research; Medicine, Experimental; Memory; Multivariate mixed model; Neurodegenerative disease; Neuroimaging; Neuropathology; Neuropsychology; Proteins; Risk factors; Santé publique et épidémiologie
• ISSN: 1471-2288; 1471-2288
• DOI: 10.1186/s12874-023-02009-0

Background Alzheimer's disease and related dementia (ADRD) are characterized by multiple and progressive anatomo-clinical changes including accumulation of abnormal proteins in the brain, brain atrophy and severe cognitive impairment. Understanding the sequence and timing of these changes is of primary importance to gain insight into the disease natural history and ultimately allow earlier diagnosis. Yet, modeling changes over disease course from cohort data is challenging as the usual timescales (time since inclusion, chronological age) are inappropriate and time-to-clinical diagnosis is available on small subsamples of participants with short follow-up durations prior to diagnosis. One solution to circumvent this challenge is to define the disease time as a latent variable. Methods We developed a multivariate mixed model approach that realigns individual trajectories into the latent disease time to describe disease progression. In contrast with the existing literature, our methodology exploits the clinical diagnosis information as a partially observed and approximate reference to guide the estimation of the latent disease time. The model estimation was carried out in the Bayesian Framework using Stan. We applied the methodology to the MEMENTO study, a French multicentric clinic-based cohort of 2186 participants with 5-year intensive follow-up. Repeated measures of 12 ADRD markers stemmed from cerebrospinal fluid (CSF), brain imaging and cognitive tests were analyzed. Results The estimated latent disease time spanned over twenty years before the clinical diagnosis. Considering the profile of a woman aged 70 with a high level of education and APOE4 carrier (the main genetic risk factor for ADRD), CSF markers of tau proteins accumulation preceded markers of brain atrophy by 5 years and cognitive decline by 10 years. However we observed that individual characteristics could substantially modify the sequence and timing of these changes, in particular for CSF level of A[formula omitted]. Conclusion By leveraging the available clinical diagnosis timing information, our disease progression model does not only realign trajectories into the most homogeneous way. It accounts for the inherent residual inter-individual variability in dementia progression to describe the long-term anatomo-clinical degradations according to the years preceding clinical diagnosis, and to provide clinically meaningful information on the sequence of events. Trial registration clinicaltria